How does KESIMPTA®▼ (ofatumumab) work?
KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.1
For full safety information, please refer to the KESIMPTA Summary of Product Characteristics (SmPC).1
KESIMPTA has been shown to act on B-cells in MS patients, targeting them and inducing cell lysis.1 KESIMPTA is an anti-CD20 monoclonal immunoglobulin G1 (IgG1) antibody that selectively targets and binds to the CD20 protein.1 This protein is expressed on the surface of the majority of B-cells, making it a valuable target for precise MS treatment.2 KESIMPTA is thought to work by selectively binding to sites on both the small and the large extracellular loops of CD20 protein on B-cells.2–4
The precise mechanism of action by which KESIMPTA exerts its therapeutic effects is unknown.
To learn about how KESIMPTA targets B-cell subsets that facilitate inflammation, and how it causes CD20-inducing lysis of these B-cells, watch this short video.1
VIDEO
CD, cluster of differentiation; IgG, immunoglobulin G; MS, multiple sclerosis; RMS, relapsing multiple sclerosis.
References:
KESIMPTA (ofatumumab) Summary of Product Characteristics.
Zhang B. mAbs 2009;1(4):326–331.
Gupta IV & Jewell RC. Ann N Y Acad Sci 2012;1263:43–56.
Martin R, et al. Eur J Immunol 2016;46:2078–2090.
UK | January 2025 | 443403
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
